123 related articles for article (PubMed ID: 29908912)
1. Oral N-acetylcysteine in the treatment of obsessive-compulsive disorder: A systematic review of the clinical evidence.
Couto JP; Moreira R
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():245-254. PubMed ID: 29908912
[TBL] [Abstract][Full Text] [Related]
2. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study.
Li F; Welling MC; Johnson JA; Coughlin C; Mulqueen J; Jakubovski E; Coury S; Landeros-Weisenberger A; Bloch MH
J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):32-37. PubMed ID: 31800306
[No Abstract] [Full Text] [Related]
3. "N-Acetylcysteine for Obsessive-Compulsive and Related Disorders in Children and Adolescents: A Review".
Parli GM; Gales MA; Gales BJ
Ann Pharmacother; 2023 Jul; 57(7):847-854. PubMed ID: 36384314
[TBL] [Abstract][Full Text] [Related]
4. N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study.
Sarris J; Oliver G; Camfield DA; Dean OM; Dowling N; Smith DJ; Murphy J; Menon R; Berk M; Blair-West S; Ng CH
CNS Drugs; 2015 Sep; 29(9):801-9. PubMed ID: 26374743
[TBL] [Abstract][Full Text] [Related]
5. What Future Role Might N-Acetyl-Cysteine Have in the Treatment of Obsessive Compulsive and Grooming Disorders?: A Systematic Review.
Smith L; Tracy DK; Giaroli G
J Clin Psychopharmacol; 2016 Feb; 36(1):57-62. PubMed ID: 26629962
[TBL] [Abstract][Full Text] [Related]
6. Second-generation antipsychotics for obsessive compulsive disorder.
Komossa K; Depping AM; Meyer M; Kissling W; Leucht S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008141. PubMed ID: 21154394
[TBL] [Abstract][Full Text] [Related]
7. N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial.
Bloch MH; Panza KE; Yaffa A; Alvarenga PG; Jakubovski E; Mulqueen JM; Landeros-Weisenberger A; Leckman JF
J Child Adolesc Psychopharmacol; 2016 May; 26(4):327-34. PubMed ID: 27027204
[TBL] [Abstract][Full Text] [Related]
8. A review of N-acetylcysteine in the treatment of grooming disorders.
Braun TL; Patel V; DeBord LC; Rosen T
Int J Dermatol; 2019 Apr; 58(4):502-510. PubMed ID: 30667049
[TBL] [Abstract][Full Text] [Related]
9. [Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature].
Etain B; Bonnet-Perrin E
Encephale; 2001; 27(3):280-9. PubMed ID: 11488259
[TBL] [Abstract][Full Text] [Related]
10. The use of psychotropic agents for the symptoms of obsessive-compulsive disorder.
Brakoulias V; Starcevic V; Berle D; Milicevic D; Moses K; Hannan A; Sammut P; Martin A
Australas Psychiatry; 2013 Apr; 21(2):117-21. PubMed ID: 23426097
[TBL] [Abstract][Full Text] [Related]
11. N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial.
Sarris J; Byrne G; Castle D; Bousman C; Oliver G; Cribb L; Blair-West S; Brakoulias V; Camfield D; Ee C; Chamoli S; Boschen M; Dean OM; Dowling N; Menon R; Murphy J; Metri NJ; Nguyen TP; Wong A; Jordan R; Karamacoska D; Rossell SL; Berk M; Ng CH
Prog Neuropsychopharmacol Biol Psychiatry; 2022 Jul; 117():110550. PubMed ID: 35304155
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of N-Acetylcysteine Augmentation on Obsessive Compulsive Disorder: A Multicenter Randomized Double Blind Placebo Controlled Clinical Trial.
Ghanizadeh A; Mohammadi MR; Bahraini S; Keshavarzi Z; Firoozabadi A; Alavi Shoshtari A
Iran J Psychiatry; 2017 Apr; 12(2):134-141. PubMed ID: 28659986
[No Abstract] [Full Text] [Related]
13. N-Acetyl Cysteine and Vitamin D Supplementation in Treatment Resistant Obsessive-compulsive Disorder Patients: A General Review.
di Michele F; Siracusano A; Talamo A; Niolu C
Curr Pharm Des; 2018; 24(17):1832-1838. PubMed ID: 29663874
[TBL] [Abstract][Full Text] [Related]
14. N-acetylcysteine blocks serotonin 1B agonist-induced OCD-related behavior in mice.
Allen EM; Hughes EF; Anderson CJ; Woehrle NS
Behav Neurosci; 2018 Aug; 132(4):258-268. PubMed ID: 29985009
[TBL] [Abstract][Full Text] [Related]
15. Dorsal anterior cingulotomy and anterior capsulotomy for severe, refractory obsessive-compulsive disorder: a systematic review of observational studies.
Brown LT; Mikell CB; Youngerman BE; Zhang Y; McKhann GM; Sheth SA
J Neurosurg; 2016 Jan; 124(1):77-89. PubMed ID: 26252455
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the efficacy of Withania somnifera (Ashwagandha) root extract in patients with obsessive-compulsive disorder: A randomized double-blind placebo-controlled trial.
Jahanbakhsh SP; Manteghi AA; Emami SA; Mahyari S; Gholampour B; Mohammadpour AH; Sahebkar A
Complement Ther Med; 2016 Aug; 27():25-9. PubMed ID: 27515872
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of treatments for patients with obsessive-compulsive disorder: a systematic review.
Choi YJ
J Am Acad Nurse Pract; 2009 Apr; 21(4):207-13. PubMed ID: 19366379
[TBL] [Abstract][Full Text] [Related]
18. Donepezil as Add-on Treatment for Resistant Obsessive-Compulsive Disorder: Retrospective Case Series.
Bergman J; Miodownik C; Lerner PP; Miodownik E; Shulkin A; Lerner V
Clin Neuropharmacol; 2016; 39(4):194-6. PubMed ID: 27223667
[TBL] [Abstract][Full Text] [Related]
19. Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder.
Marinova Z; Chuang DM; Fineberg N
Curr Neuropharmacol; 2017; 15(7):977-995. PubMed ID: 28322166
[TBL] [Abstract][Full Text] [Related]
20. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study.
Arabzadeh S; Shahhossenie M; Mesgarpour B; Rezaei F; Shalbafan MR; Ghiasi Z; Akhondzadeh S
Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28485008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
